Record of Telephone Conversation, December 15, 2011 - Flucelvax
Submission Type: BLA Submission ID: 125408/0 Office: OVRR
Influenza Vaccine (MDCK Cells)
Novartis Vaccines and Diagnostics GmbH
Telecon Date/Time: 15-Dec-2011 09:59 AM Initiated by FDA? Yes
Telephone Number: Communication conveyed via e-mail
Author: TIMOTHY FRITZ
Advice to submit request for new proprietary name review.
FDA Participants: Timothy Fritz
Non-FDA Participants: Ingeborg Cebulla, John Barry
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
From: Fritz, Timothy
Sent: Thursday, December 15, 2011 9:59 AM
Subject: Optaflu Proprietary Name Review Request
Dear Dr. Cebulla-
CBER’s July 19, 2007, letter issued under IND 11580 in reference to the proprietary name review of OPTAFLU stated that Novartis Vaccines and Diagnostics, Inc is required to request a new proprietary name review of OPTAFLU if more than 90 days have passed since the date of the CBER letter and licensure of OPTAFLU. Because this condition has been met, Novartis is required to submit a request for a new proprietary name review for OPTAFLU. Please submit this request as an amendment to the OPTAFLU BLA (STN 125408) and provide CBER with any updated information regarding the proposed OPTAFLU name. It is not necessary for Novartis to resubmit the information already provided on September 29, 2006, to IND 11580 as copied in Module 1.12.4 of the OPTAFLU BLA original submission.
If you have any questions, please contact the Regulator Project Managers, Dr. Brenda Baldwin or Dr. Timothy Fritz, at 301-796-2640 or via e-mail.
Timothy A. Fritz, Ph.D.
1451 Rockville Pike
Rockville, MD 20852
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.